Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-05T12:55:00.249Z Has data issue: false hasContentIssue false

Crystal structure and X-ray powder diffraction data for ruxolitinib

Published online by Cambridge University Press:  23 January 2023

Chunguang Dai
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310027, PR China Zhejiang Ausun Pharmaceutical Co., Ltd, Taizhou 307016, PR China
Yuanjiang Pan
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310027, PR China
Xiurong Hu*
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310027, PR China
*
a)Author to whom correspondence should be addressed. Electronic mail: huxiurong@zju.edu.cn

Abstract

X-ray powder diffraction data, unit-cell parameters, and space group for ruxolitinib are reported [a = 8.7211(5) Å, b = 19.6157(15) Å, c = 18.9645(10) Å, β = 90.903(6)°, unit-cell volume V = 3243.85 Å3, Z = 8, and space group P21]. All measured lines were indexed and are consistent with the corresponding space group. No detectable impurities were observed. The single-crystal data of ruxolitinib are also reported [space group P21, a = 8.7110(2) Å, b = 19.5857(4) Å, c = 18.9372(4) Å, β = 90.8570(10)°, unit-cell volume V = 3230.53(10) Å3, Z = 8]. The experimental powder diffraction pattern has been well matched with the simulated pattern derived from the single-crystal data.

Type
New Diffraction Data
Copyright
Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of International Centre for Diffraction Data

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Albrecht, W., & Selig, R.. 2016. “Salts of (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-LH-pyrazole-L-yl)-3-Cyclopentylpropanenitrile with Benzenesulfonic Acid,” the Patent Corporate Body Aruga Patent Office WO2016026975A.Google Scholar
Bernal-Vazquez, P. M., Lazcano-Seres, J. M., Juarez-Lagunas, J. A., Cano-Herrera, M. D. L. A., Van, D. K. M., Cedillo-Cruz, A., & Mendoza, R. J. M.. 2016. “Solid Form of Ruxolitinib,” the Patent Corporate Body Aruga Patent Office CA2928286A.Google Scholar
Brandenburg, K., & Putz, H.. 2005. Diamond-Crystal and Molecular Structure Visualization. Bonn, Germany, Crystal Impact GbR.Google Scholar
Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., and Puschmann, H.. 2009. “OLEX2: A Complete Structure Solution, Refinement and Analysis Program.” Journal of Applied Crystallography 42: 339–41.CrossRefGoogle Scholar
Gates-Rector, S., and Blanton, T.. 2019. “The Powder Diffraction File: A Quality Materials Characterization Database.” Powder Diffraction 34: 352–60.CrossRefGoogle Scholar
Groom, C. R., Bruno, I. J., Lightfoot, M. P., and Ward, S. C.. 2016. “The Cambridge Structural Database.” Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials 72: 171–9.Google ScholarPubMed
Lussana, F., Cattaneo, M., Rambaldi, A., and Squizzato, A.. 2018. “Ruxolitinib-Associated Infections: A Systematic Review and Meta-Analysis.” American Journal of Hematology 93: 339–47.CrossRefGoogle ScholarPubMed
Materials Data Inc. (MDI). 2002. Jade 7.5 XRD Pattern Processing Software. Livermore, CA, USA, Materials Data.Google Scholar
Plosker, G. L. 2015. “Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis.” Drugs 75: 297308.CrossRefGoogle ScholarPubMed
Sheldrick, G. M. 2015a. “SHELXT - Integrated Space-Group and Crystal-Structure Determination.” Acta Crystallographica. Section A, Foundations and Advances A71: 38.CrossRefGoogle Scholar
Sheldrick, G. M. 2015b. “Crystal Structure Refinement with SHELXL.” Acta Crystallographica. Section A, Foundations and Advances C71: 38.CrossRefGoogle Scholar
Smith, G. S., and Snyder, R. L.. 1979. “FN: A Criterion for Rating Powder Diffraction Patterns and Evaluating the Reliability of Powder-Pattern Indexing.” Journal of Applied Crystallography 12: 60–5.CrossRefGoogle Scholar
Tieger, E., Tozickova, H., Tkadlecova, M., Dammer, O., & Gurgut, T.. 2017. “Crystalline Forms of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-pyrazol-L-yl]-Propanenitrile Salts and Preparation Thereof,” the Patent Corporate Body Aruga Patent Office WO2017125097A.Google Scholar